President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...

On the cusp of seeking to become a commercial cancer company, Immunocore raised $75 million in a series C round. The news comes less than two months after Oxford, U.K.-based Immunocore Ltd. announced the first...

Encountering unanticipated investor interest after closing its series A round,  RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make...

The COVID R&D Alliance is looking beyond the imminent rollout of vaccines, anticipating an ongoing need for effective therapies in hospitalized COVID-19 patients. Last week, it launched the COMMUNITY...

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...